Demand
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2
TMO
FY2026 Q2
상향
Thermo Fisher Scientific Inc 실적 발표
Buzzberg 분석
Revenue grew 10% to $11.99 billion
Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance.
Buzzberg 분석 Revenue grew 10% to $11.99 billion Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance. 전체 분석 보기분석 접기
Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance.
- Full-year revenue guidance raised to $47.4-48.1B; EPS raised to $24.93-25.33.
- Pharma/biotech end market grew mid-single digits with strong bioproduction and clinical research.
- Academic/government grew low single digits, returning to growth; US positive.
매출$11.994B+9% 전분기 대비
주당순이익(EPS)$6.03+11% 전분기 대비
매출총이익률41.21%보고값
영업이익률17.4%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Margins
Adjusted operating margin expanded 90 bps to 22.8%
Guidance
Raised full-year revenue guidance to $47.4-$48.1B
핵심 내용 3개 더 보기
Capital return
Deployed $1.2B to shareholders via buybacks and dividends
Demand
Bioproduction had another quarter of excellent growth
Other
Actively deploying AI across the company
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $11.994B | +9% 전분기 대비 |
| 주당순이익(EPS) | $6.03 | +11% 전분기 대비 |
| 매출총이익률 | 41.21% | 보고값 |
| 영업이익률 | 17.4% | 보고값 |
| 잉여현금흐름 | $1.675B | 보고값 |
| 자본지출 | $0.45B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $24.93–$25.33 | $25.13 | 상향 |
| 매출 | FY2026 | $47.4B–$48.1B | $47.75B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
confident
Management struck a confident tone, citing an outstanding quarter, a clean top and bottom line beat, and raising full-year guidance. The tone was driven by strong customer activity across end markets and excellent operational execution.
경영진의 AI 분석
Management discussed launching next-generation Orbitrap platforms and AI-driven capabilities at the ASMS conference, and stated they are actively deploying AI across the company to further accelerate PPI's impact.
투자 및 생산능력
Net capital expenditures for 2026 are expected to be between $1.9 and $2.1 billion; $800 million was spent in the first half. Management also noted they are increasing capacity for the filtration and separation business.
아래에 언급된 기업 2개 모두 표시
기업발표 이후 수익률
공급망
공급망
Marc Casper
Electron microscopy strength partly attributed to semiconductor enabling role, with strong bookings growth. — Suggests ongoing capital equipment demand in semiconductor manufacturing, benefiting tool suppliers and potentially reinforcing capex cycle narratives.
근거
“Within electron microscopy, another really good quarter, semiconductor, we play a key enabling role there”
외부 신호
공급망 알파 · 2발표 이후 수익률
Chemical analysis business growth was driven by higher commodity prices and increased demand for safety/security applications (radiation and explosives detection) due to global conflict.
근거
“We also saw an increase in demand for safety and security applications as well, given the amount of conflict going on in the world.”
Electron microscopy strength partly attributed to semiconductor enabling role, with strong bookings growth.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 2개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.